1 Measuring changes in *Plasmodium falciparum* census population size in

2

response to sequential malaria control interventions

4 5 6 7	Kathryn E. Tiedje ^{1,2§} , Qi Zhan ^{3,4§} , Shazia Ruybal-Pésantez ^{2†} , Gerry Tonkin-Hill ^{2,5} , Qixin He ^{4‡} , Mun Hua Tan ¹ , Dionne C. Argyropoulos ¹ , Samantha L. Deed ^{1,2} , Anita Ghansah ⁶ , Oscar Bangre ⁷ , Abraham R. Oduro ⁷ , Kwadwo A. Koram ⁸ , Mercedes Pascual ^{9,10} , and Karen P. Day ^{1,2}
8	¹ Department of Microbiology and Immunology, Bio21 Institute and Peter Doherty Institute, The
9	University of Melbourne; Melbourne, Australia
10	² School of BioSciences, Bio21 Institute, The University of Melbourne; Melbourne, Australia
11 12	³ Committee on Genetics, Genomics and Systems Biology, The University of Chicago; Chicago, Illinois, USA
13 14	⁴ Department of Ecology and Evolution, The University of Chicago; Chicago, Illinois, USA ⁵ Bioinformatics Division, Walter and Eliza Hall Institute: Melbourne, Australia
15 16	⁶ Department of Parasitology, Noguchi Memorial Institute for Medical Research, University of Ghana; Legon, Ghana
17	⁷ Navrongo Health Research Centre, Ghana Health Service; Navrongo, Ghana
18 19	⁸ Epidemiology Department, Noguchi Memorial Institute for Medical Research, University of Ghana; Legon, Ghana
20 21	⁹ Department of Biology and Department of Environmental Sciences, New York University, New York, New York, USA
22	¹⁰ Santa Fe Institute, Santa Fe, New Mexico, USA
23	
24	
25	<i>† Current affiliations:</i> Department of Infectious Disease Epidemiology and MRC Centre for Global
26 27	Infectious Disease Analysis, School of Public Health, Imperial College London, United Kingdom
28 29	<i>‡ Current affiliation:</i> Department of Biological Sciences, Purdue University; West Lafayette, United States
30 31	§ These authors share first authorship
32	* Corresponding Author: Karen P. Day, Department of Microbiology and Immunology, Bio21 Institute
33	and Peter Doherty Institute, The University of Melbourne, 30 Flemington Road, Parkville. VIC. 3011.
34	Australia. E-mail: <u>Karen.Day@unimelb.edu.au</u> , Phone: +613 8344 2377
35	
36	RUNNING TITLE: Impact of IRS and SMC on census population size

37 ABSTRACT

38 Here we introduce a new endpoint "census population size" to evaluate the epidemiology and control of 39 Plasmodium falciparum infections, where the parasite, rather than the infected human host, is the unit of 40 measurement. To calculate census population size, we rely on a definition of parasite variation known as 41 multiplicity of infection (MOl_{var}), based on the hyper-diversity of the var multigene family. We present a 42 Bayesian approach to estimate MOl_{var} from sequencing and counting the number of unique DBL α tags (or 43 DBL α types) of var genes, and derive from it census population size by summation of MOI_{var} in the human 44 population. We track changes in this parasite population size and structure through sequential malaria 45 interventions by indoor residual spraying (IRS) and seasonal malaria chemoprevention (SMC) from 2012 46 to 2017 in an area of high-seasonal malaria transmission in northern Ghana. Following IRS, which reduced 47 transmission intensity by > 90% and decreased parasite prevalence by \sim 40-50%, significant reductions in 48 var diversity, MOIvar, and population size were observed in ~2,000 humans across all ages. These changes, 49 consistent with the loss of diverse parasite genomes, were short lived and 32-months after IRS was 50 discontinued and SMC was introduced, var diversity and population size rebounded in all age groups 51 except for the younger children (1-5 years) targeted by SMC. Despite major perturbations from IRS and 52 SMC interventions, the parasite population remained very large and retained the var population genetic characteristics of a high-transmission system (high var diversity; low var repertoire similarity) 53 54 demonstrating the resilience of *P. falciparum* to short-term interventions in high-burden countries of sub-55 Saharan Africa.

57 INTRODUCTION

58 Malaria in high-transmission endemic areas of sub-Saharan Africa (SSA) is characterised by vast diversity 59 of the *Plasmodium falciparum* parasites from the perspective of antigenic variation (Chen et al., 2011; Day 60 et al., 2017; Otto et al., 2019; Ruybal-Pesántez et al., 2022, 2017). As with other hosts of hyper-variable 61 pathogens (Futse et al., 2008), children experiencing clinical episodes of malaria, eventually become 62 immune to disease but not to infection. This results in a large reservoir of chronic asymptomatic infections, 63 in hosts of all ages, sustaining transmission to mosquitos. Given the goal of malaria eradication by 2050, 64 it is therefore of interest to examine how the parasite population changes following perturbation by major intervention efforts, both in terms of its size and underlying population genetics. 65

66

67 So, what do we mean by the parasite population size in the case of *P. falciparum* and how do we measure 68 it? Parasite prevalence, detected by microscopy or more sensitive molecular diagnostics (e.g., PCR), 69 describes the proportion of infected human hosts. Studies of *P. falciparum* genetic diversity have shown 70 that the majority of people in high-transmission endemic areas harbour diverse multiclonal infections 71 measured as the complexity or multiplicity of infection (MOI) (e.g., (Anderson et al., 2000; Paul et al., 72 1995; Smith et al., 1999; Sumner et al., 2021)) with complex population dynamics (Bruce et al., 2000; 73 Farnert et al., 1997). These genetic data indicate much larger parasite population sizes than observed by 74 prevalence of infection alone. Thus, from an ecological perspective, we can consider a human host as a 75 patch carrying a number of "antigenically-distinct infections" of *P. falciparum*. The sum of these 76 antigenically-distinct infections over all hosts provides us with a census of the parasite count of relevance 77 to monitoring and evaluating malaria interventions. We refer to this census population size hereafter

simply as population size but make clear that this measure is distinct from effective population size (N_e) as measured by neutral variation.

80

81 Diversity of *P. falciparum* single copy surface antigen genes such as circumsporozoite protein (*csp*), 82 merozoite surface protein 1 (msp1) or 2 (msp2), and apical membrane antigen 1 (ama1) have each been 83 widely used to measure MOI (e.g., (Falk et al., 2006; Lerch et al., 2017; Nelson et al., 2019)). They have 84 become part of newer genetic panels (e.g., Paragon v1 (Tessema et al., 2020) and AMPLseq v1 (LaVerriere 85 et al., 2022)) specifically for MOI determination. Typically, MOI is reported as the maximum number of 86 alleles or single locus haplotypes present at the most diverse of these antigen-encoding loci rather than 87 the number of unique multilocus haplotypes of these genes combined, as it is challenging to accurately 88 reconstruct or phase these haplotypes in hosts with an MOI > 3 (Lerch et al., 2019). Each of these genes 89 is under balancing selection with a few geographically-common haplotypes and many very rare haplotypes 90 in moderate- to high-transmission settings (Markwalter et al., 2022; Sumner et al., 2021). Where there is 91 a high probability of co-occurrence of two or more common single locus haplotypes in a host, genotyping 92 each of these single copy antigen genes alone will underestimate MOI. Single nucleotide polymorphism 93 (SNP) panels have been used to define the presence of multiclonal infections with limited reliability to 94 estimate MOI for highly complex infections, typical in high transmission, even with the use of 95 computational methods (Labbé et al., 2023).

96

As an alternative to genotyping single copy antigen genes and biallelic SNP panels to estimate MOI, we
have proposed the use of a fingerprinting methodology known as *var*coding to genotype the hyper-diverse *var* multigene family (~50-60 *var* genes per haploid genome). This method employs a ~450bp region of a

100 var gene, known as a DBL α tag encoding the immunogenic Duffy-binding-like alpha (DBL α) domain of 101 PfEMP1 (Plasmodium falciparum erythrocyte membrane protein 1), the major surface antigen of the 102 blood stages (Zhang and Deitsch, 2022). Bioinformatic analyses of a large database of exon 1 sequences of var genes showed a predominantly 1-to-1 DBL α -var relationship, such that each DBL α tag typically 103 104 represents a unique var gene, especially in high transmission (Tan et al., 2023). The extensive diversity of 105 DBL α tags together with the very low percentage of var genes shared between parasites (Chen et al., 106 2011; Day et al., 2017; Ruybal-Pesántez et al., 2022, 2017) facilitate measuring MOI by amplifying, pooling, 107 sequencing, and counting the number of unique DBL α tags (or DBL α types) in a host (Ruybal-Pesántez et 108 al., 2022; Tiedje et al., 2022). From a single PCR with degenerate primers and amplicon sequencing, the 109 method specifically counts the most diverse DBL α types, designated non-upsA, per infection to arrive at 110 a metric we call MOIvar. It is not based on assigning haplotypes but exploits the fact that var repertoires 111 are non-overlapping, especially in high transmission. Instead, it assumes a set number of non-upsA types 112 per genome based on repeated sampling of 3D7 control isolates accounting for PCR sampling errors to 113 calculate MOI_{var} (Ghansah et al., 2023; Ruybal-Pesántez et al., 2022; Tiedje et al., 2022). Consequently, 114 rather than looking at the diversity of a single copy antigen-encoding gene like csp, msp2, or ama1 to 115 calculate MOI, by varcoding we are looking at sets of up to 45 non-upsA DBLa types per genome. Prior 116 work has shown that varcoding is more sensitive to measure MOI in high transmission where there is an 117 extremely high prevalence of multiclonal infections that cannot be accurately phased with either biallelic 118 SNP panels (Ghansah et al., 2023; Labbé et al., 2023; Tessema et al., 2020; Watson et al., 2021) or 119 combinations of single copy antigen genes (Sumner et al., 2021).

120

121 Here we report an investigation of changes in parasite census population size and structure through two 122 sequential malaria control interventions between 2012 and 2017 in Bongo District located in the Upper 123 East Region of Ghana, one of the 12 highest burden countries in Africa (World Health Organization, 2022). 124 We present a novel Bayesian modification to the published varcoding approach (Ghansah et al., 2023; 125 Ruybal-Pesántez et al., 2022; Tiedje et al., 2022) that takes into account under-sampling of non-upsA 126 DBLa types in an isolate to estimate MOIvar (Ruybal-Pesántez et al., 2022; Tiedje et al., 2022) and therefore 127 population size. We document *P. falciparum* prevalence as well as *var* diversity and population structure 128 from baseline in 2012 through a major perturbation by a short-term indoor residual spraying (IRS) 129 campaign managed under operational conditions, which reduced transmission intensity by > 90% as 130 measured by the entomological inoculation rate (EIR) and decreased parasite prevalence by ~40-50% 131 (Tiedje et al., 2022). Next, we followed what happened to parasite population size more than two years 132 after the IRS intervention was discontinued and seasonal malaria chemoprevention (SMC) was introduced 133 for children between the ages of 3-59 months (i.e., < 5 years) (Wagman et al., 2018). Detectable changes 134 in parasite population size were seen as a consequence of the IRS intervention but this quantity rapidly 135 rebounded 32-months after the intervention ceased. Overall, throughout the IRS, SMC, and subsequent 136 rebound, the parasite population in humans remained large in size and retained the var population 137 genetic characteristics of high transmission (i.e., high var diversity, low var repertoire overlap), 138 demonstrating the overall resilience of the species to survive significant short-term perturbations.

139 MATERIALS AND METHODS

140 Human subject ethical approval

The study was reviewed/approved by the ethics committees at the Navrongo Health Research Centre (Ghana), Noguchi Memorial Institute for Medical Research (Ghana), The University of Melbourne (Australia), and The University of Chicago (United States). Details on the study area, study population, inclusion/exclusion criteria, and data collection procedures have been previously described (Tiedje et al., 2022, 2017).

146

147 Study design and sample collection

148 Using an interrupted time-series study design, four age-stratified cross-sectional surveys of ~2,000 149 participants per survey were undertaken to investigate the impacts of IRS and SMC in combination with 150 long-lasting insecticidal nets (LLINs) impregnated with pyrethroids under operational conditions on the 151 asymptomatic P. falciparum reservoir from two proximal catchment areas (i.e., Vea/Gowrie and Soe, with 152 a sampling area of $\sim 60 \text{ km}^2$) in Bongo District, Ghana (Tiedje et al., 2022, 2017) (Table supplement 1). Bongo District, located in the Upper East Region, is categorized as high-seasonal malaria transmission 153 154 based on the World Health Organization's (WHO) "A Framework for Malaria Elimination" (WHO/GMP, 155 2017) where *P. falciparum* prevalence was \geq 35% at baseline in 2012 (Tiedje et al., 2022, 2017). These 156 2 ,000 participants of all ages (1-97 years) represent $^{15\%}$ of the total population that reside in these 157 two catchment areas in Bongo (Tiedje et al., 2017). The four cross-sectional surveys were completed at 158 the end of the wet season (i.e., high-transmission season) and the study can be separated into four distinct 159 study time points: (1) October 2012 (Survey 1) prior to the IRS and SMC (i.e., baseline), (2) October 2014 160 (Survey 2) two months after the second round of IRS (Actellic 50EC), (3) October 2015 (Survey 3) seven

161 months after the third round of IRS using a long-acting non-pyrethroid insecticide (Actellic 300CS) (Gogue 162 et al., 2020; US President's Malaria Initiative Africa IRS (AIRS) Project, 2016), and finally (4) October 2017 163 (Survey 4) 32-months after the discontinuation of IRS, but during the deployment of SMC to all children 164 3-59 months (i.e., < 5 years) (Figure 1). LLINs (i.e., PermaNet 2.0, Olyset, or DawaPlus 2.0) were mass 165 distributed in Bongo District by the National Malaria Elimination Programme (NMEP)/Ghana Health 166 Service (GHS) between 2010-2012 and again in 2016 following the discontinuation of IRS (Gogue et al., 167 2020; Tiedje et al., 2022; US Agency for International Development (USAID) Global Health Supply Chain 168 Program, 2020). In addition, to maintain high coverage of LLINs between these campaigns continuous 169 distribution was undertaken using routine services (i.e., antenatal clinics, school distributions, 170 immunization visits, etc.) (Tiedje et al., 2022). Over the course of this study self-reported LLIN usage the 171 previous night remained high across all age groups, from 89.1% in 2012 (pre-IRS), 83.5% in 2014 (during 172 IRS), 90.6% in 2015 (post-IRS), to 96.8% in 2017 (SMC). Details on the study area, study population, and 173 data collection procedures have been previously described (Tiedje et al., 2022, 2017).

174

175 Details of the IRS and SMC interventions

Starting in 2013, the AngloGold Ashanti Malaria Control Programme (AGAMal) in a public-private partnership with the Global Fund, scaled up IRS across all of the Upper East Region of northern Ghana (Gogue et al., 2020). As part of this initiative, three rounds of IRS with organophosphate formulations (i.e., non-pyrethroid) were rolled out prior to the start of the wet season between 2013 and 2015 (Figure 1A) in Bongo District (Tiedje et al., 2022). Based on AGAMal's operational reports, IRS coverage in Bongo District was 91.8% in Round 1, 95.6% in Round 2, and finally 96.6% in Round 3 (AGAMal, personal communication). To monitor the impact of the IRS on the local vector population, monthly entomological

183 collections were undertaken between February 2013 and September 2015 (Tiedje et al., 2022). Using 184 these surveys, we observed that the monthly entomological inoculation rate (EIR) (infective 185 bites/person/month (ib/p/m)), a measure of local transmission intensity, declined by > 90% at the peak of the wet season between August 2013 (pre-IRS) (EIR = 5.3 ib/p/m) and August 2015 (post-IRS) (EIR = 0.4 186 187 ib/p/m) (Tiedje et al., 2022). Following the IRS, SMC was rolled out in the Upper East Region by the 188 NMEP)/(GHS) starting in 2016 (Gogue et al., 2020) (Figure 1A). SMC is the intermittent administration of 189 full treatment courses of an antimalarial to children between the ages of 3-59 months (i.e., < 5 years) 190 (WHO, 2012). Like other countries, the SMC drug combination of choice in Ghana is amodiaquine plus 191 sulfadoxine-pyrimethamine, which is administered at monthly intervals during the high-transmission 192 season (i.e., wet season) (WHO, 2012). The goal of this age-targeted intervention is to both clear current 193 malaria infections and prevent malarial illness by maintaining a therapeutic concentration of an 194 antimalarial in blood over the period of greatest risk (i.e., high-transmission season). Reported SMC 195 coverage in Bongo District was 92.6% in 2016 (two rounds between August – September 2016) and 94.6% 196 in 2017 (four rounds between September – December 2017) (Gogue et al., 2020).

197

198 *Var* genotyping and sequence analysis

Genomic DNA was extracted from the dried blood spots for all participants with a confirmed microscopic
asymptomatic *P. falciparum* infection (i.e., isolate) (2,572 isolates, Table supplement 2) using the QIAamp
DNA mini kit (QIAGEN, USA) as previously described (Tiedje et al., 2017). For *var* genotyping or *var*coding,
the sequence region within the *var* genes encoding the DBLα domains of PfEMP1 were amplified using a
single-step PCR, pooled, and sequenced on an Illumina platform using the MiSeq 2×300bp paired-end
protocol (Supplemental Methods, Figure supplement 1). The raw sequence data was then processed using

our previously published customized bioinformatic pipelines (Supplemental Methods, Figure supplement
206 2). For additional information on the use of these bioinformatic pipelines a detailed tutorial is available
(https://github.com/UniMelb-Day-Lab/tutorialDBLalpha).

208

209 DBL α sequencing data was obtained from 2,397 *P. falciparum* isolates (93.2%) (Table supplement 2). This 210 genotyping success was acceptable given that we were working with low-density asymptomatic infections 211 (Table supplement 1). Using a cut-off of \geq 20 DBL α types, DBL α sequencing data was obtained from 2,099 212 *P. falciparum* isolates (81.6%) with a total of 289,049 DBL α sequences and 53,238 unique DBL α types 213 being identified in the study population (Table supplement 2). The median *P. falciparum* density was ~4 214 times higher for isolates with \geq 20 DBL α types compared to those that gave no or < 20 DBL α types (520 215 [IQR: 200-1880] parasites/ μ L vs. 120 [IQR: 40-200] parasites/ μ L, respectively).

216

217 DBLa type diversity

218 We monitored the impacts of the sequential interventions (i.e., IRS and SMC) on diversity by measuring 219 changes in the population genetics of DBL α types at the population level (i.e., *P. falciparum* reservoir). 220 Diversity was monitored using two measures, DBLa type richness and DBLa type frequency. Richness was 221 defined as the number of unique DBL α types observed (i.e., DBL α type pool size) in each survey or study 222 time point (i.e., 2012, 2014, 2015, and 2017). DBLa type richness, however, does not provide any 223 information about the relative frequencies of the different DBL α types in the population, as they are all 224 weighted equally whether they are observed once or more frequently (e.g., observed in > 20 isolates per 225 survey). To further examine the impacts of the interventions on DBL α type diversity we also assessed the 226 frequency of each unique DBL α type in 2012, 2014, 2015, and 2017. Here we defined DBL α type frequency

227 as the number of times (i.e., number of isolates) a DBL α type was observed in each survey. Both upsA and 228 non-upsA DBL α type diversities were measured due to their different biological features, chromosomal 229 positions (i.e., subtelomeric regions vs. internal or central regions), as well as population genetics (Falk et 230 al., 2009; Gardner et al., 2002; Jensen et al., 2004; Kaestli et al., 2006; Kalmbach et al., 2010; Kraemer et 231 al., 2007; Kraemer and Smith, 2006; Kyriacou et al., 2006; Lavstsen et al., 2003; Normark et al., 2007; 232 Rottmann et al., 2006; Warimwe et al., 2012, 2009; Zhang and Deitsch, 2022). The proportions of upsA 233 and non-upsA var genes in a repertoire or single genome have been defined as ~15-20% and ~80-85%, 234 respectively, based on whole genome sequencing (Rask et al., 2010). The upsA and non-upsA DBL α type 235 proportions were partitioned as expected in our analyses, with the median proportions at the repertoire 236 level being comparable in 2012 (19% upsA and 81% non-upsA), 2014 (22% upsA and 78% non-upsA), 2015 237 (21% upsA and 79% non-upsA), and 2017 (20% upsA and 80% non-upsA).

238

239 Repertoire similarity as defined by pairwise type sharing

240 To estimate genetic similarity between the DBL α repertoires (i.e., unique DBL α types identified in each 241 isolate) identified from two isolates, pairwise type sharing (PTS) was calculated between all pairs of 242 isolates in each survey as previously described (Barry et al., 2007). PTS, analogous to the Sørensen Index, 243 is a similarity statistic to evaluate the proportion of DBLa types shared between two isolate repertoires 244 (i.e., DBLa repertoire overlap) and ranges from 0 (i.e., no DBLa repertoire overlap) to 1 (i.e., identical DBLa 245 isolate repertoires), where < 0.50 = unrelated, 0.5 = recent recombinants/siblings, > 0.5 = related, and 1 246 = clones. PTS is a measure of identity-by-state (IBS) used to assess repertoire similarity between isolates 247 and is not used to infer inheritance from a recent common ancestor (i.e., identity-by-decent (IBD)) (Speed 248 and Balding, 2015).

249

250 DBLα isolate repertoire size

251 For this study we have exploited the unique population structure of non-overlapping DBL α isolate 252 repertoires to estimate isolate MOI_{var} . To calculate MOI_{var} , the non-upsA DBL α types were chosen since 253 not only are they more diverse and less conserved between isolate repertoires (i.e., low median PTS_{non-} 254 $\mu_{\text{UDSA}} \leq 0.020$) compared to the upsA DBL α types, but they have also been shown to have a more specific 1-255 to-1 relationship with a single var gene than upsA (Tan et al., 2023). The low to non-existent overlap of 256 repertoires enables an estimation of MOI that relies on the number of non-upsA DBLa types sequenced 257 from an individual's isolate (Ruybal-Pesántez et al., 2022; Tiedje et al., 2022). A constant repertoire size 258 or number of DBL α types in a parasite genome can be used to convert the number of types sequenced in 259 an isolate to estimate MOI (Ruybal-Pesántez et al., 2022; Tiedje et al., 2022). This approach, however, 260 neglects the measurement error in this size introduced by targeted PCR and amplicon sequencing of var 261 genes in an isolate.

262

263 Bayesian estimation of MOIvar and associated census population size

Here, we extend the method to a Bayesian formulation and estimate the posterior distribution for each sampled individual for the probability of different MOI values. From individual posterior distributions, we can then obtain the estimated MOI frequency distribution for the population as a whole. The two pieces of information required for our approach are the measurement error and the prior distribution of MOI. The measurement error is simply the repertoire size distribution, that is, the distribution of the number of non-upsA DBL α types sequenced given MOI = 1, which is empirically available (Figure supplement 3 (Labbé et al., 2023)). We refer to it as P(s | MOI = 1) where *s* here denotes repertoire size. More generally when MOI \ge 1, *s* denotes the number of non-upsA DBLa types sequenced or isolate size. The prior distribution of MOI refers to the belief we have for what the actual MOI distribution might look like at the population level before empirical evidence is taken into consideration. For example, the prior distribution of MOI is likely to centre around a higher value in high-transmission endemic areas than in lowtransmission ones.

276

We can obtain $P(s \mid MOI = m)$ from the serial convolution of the repertoire size distribution $P(s \mid MOI =$ 1) and $P(s \mid MOI = m - 1)$. Starting with the repertoire size distribution given a single infection, we can derive $P(s \mid MOI = m)$ for *m* equal to 2,3,..., up until a maximum value of 20 (empirically determined), as follows:

$$P(s | MOI = m) = \sum_{x=L}^{U} P(x | MOI = 1) \times P(s - x | MOI = m - 1)$$
281
1.1

where L and U are the lower and upper limit for the repertoire size, 10 and 45 respectively from the
empirical repertoire size distribution (Figure supplement 3 (Labbé et al., 2023)).

284

285 For simplicity, we begin with a uniform prior. We use Bayes' rule to derive a posterior distribution of

286 MOI given a certain number of non-upsA DBLα types sequenced from an individual:

$$P(MOI = j \mid s) = \frac{P(s \mid MOI = j) \times P(MOI = j)}{\sum_{i=1}^{k} P(s \mid MOI = i) \times P(MOI = i)}$$
1.2

where k is the maximum value of MOI, here 20, as empirically determined.

289

To obtain the MOI distribution at the population level, we could either simply pool the maximum *a posteriori* MOI estimate for each sampled individual, or use a technique called mixture distribution. For the latter, we weighed each posterior MOI distribution for each sampled individual equally and sum over all posterior distributions at the individual level to derive the MOI distribution at the population level:

$$f(MOI = m) = \sum_{i=1}^{n} \frac{1}{n} P(MOI = m | s_i)$$
1.3

295 where *n* is the number of sampled individuals. These two approaches gave similar results for our empirical 296 survey data as determined by the Kolmogorov-Smirnov Test. The obtained distance statistic is close to 0 297 and the corresponding *p*-value is non-significant across all surveys, indicating that the two estimates were 298 drawn from the same distribution (Table supplements 3 and 4). Additionally, the difference between the 299 mean MOI values at the population level obtained from the two approaches is small (Table supplements 300 3 and 4). Given this similarity, we present the results based on pooling the maximum *a posteriori* MOI 301 estimates for each sampled individual in the main text and include the results based on mixture 302 distribution in the Supplemental Information. Note that we focused on individuals who had confirmed 303 microscopic asymptomatic P. *falciparum* infections for our MOI estimation.

304

294

To examine alternative priors, we considered empirical MOI distributions described in the literature including the Poisson, hyper-Poisson, and negative binomial distributions (Dietz, 1988; Henry, 2020). The hyper-Poisson and negative binomial distributions can capture the overdispersion seen in the empirical distribution of MOI for certain areas and caused by factors such as heterogeneous biting. We therefore focused on a negative binomial distribution and investigated changing its parameters to generate priors with different means spanning a wide range of MOI values (mean MOI within [~1.5, ~6.7]), including those

seen in high-transmission endemic areas. A uniform prior and a zero-truncated negative binomial 311 312 distribution with parameters within the range typical of high-transmission endemic regions (higher mean 313 MOI, for example, ~4.3 versus ~6.7, with tails for higher MOI values in the range of 10-20) produce similar 314 MOI estimates at the population level (Table supplements 5 and 6). However, when setting the parameter 315 range of the zero-truncated negative binomial to be representative of those in low-transmission endemic 316 regions where the empirical MOI distribution centres around monoclonal infections with the majority of 317 MOIs = 1 or 2 (mean MOI \approx 1.5, no tail at higher MOI values), the final population-level MOI distribution 318 does deviate more from that based on the aforementioned prior and parameter choices (Table 319 supplement 6). The final individual- and population-level MOI estimates are not sensitive to the specifics 320 of the prior MOI distribution as long as this distribution captures the tail for higher MOI values with abovezero probability. The obtained Kolmogorov-Smirnov Test distance statistics and their corresponding p-321 322 values, the Pearson correlation tests and their corresponding *p*-values, as well as the difference in mean 323 MOI values, for the comparison of the MOI estimates obtained with the different priors are included in 324 Table supplements 5 and 6. Given these comparisons, we provide in our analyses the estimated 325 population MOI distribution using a uniform prior.

326

327 Statistical analysis

We used the R v4.3.1 for all data analyses with the collection of R packages in *tidyverse* being used for data curation along with *base, stats, gtsummary,* and *epiR* for the statistical analyses (R Core Team, 2018; Sjoberg, D et al., 2021; Stevenson, 2020; Wickham et al., 2019). Continuous variables are presented as medians with interquartile ranges (IQRs) and discrete variables are presented using the observed or calculated values with the 95% confidence interval (95% CIs) or ± 2 standard deviations (± 2SD). Kaplan-

- 333 Meier survival curves were generated for the time (i.e., number of surveys) to first event (i.e., when the
- 334 DBLa type was no longer observed/detected) comparing the upsA and non-upsA DBLa types; *p-values*
- 335 were determined using the log-rank test using the R packages survival and survminer (Kassambara et al.,
- 336 2021; Therneau, 2023). The time interval to first event considered for all survival curves was the number
- of surveys or year (i.e., 2012, 2014, 2015, and 2017) that each DBLα type was observed and only includes
- 338 those upsA (N = 2,218) and non-upsA (N = 33,159) DBL α types that were seen at baseline in 2012 (i.e.,
- 339 those DBL α types observed prior to the IRS intervention) (Table supplement 2).

341 **RESULTS**

342 Between 2013 and 2015, three-rounds of IRS with non-pyrethroid insecticides were implemented across 343 all of Bongo District. Coincident with the > 90% decrease in transmission following IRS (Tiedje et al., 2022), 344 the prevalence of microscopic *P. falciparum* infections compared to the 2012 baseline survey (pre-IRS) 345 declined by 45.2% and 35.7% following the second (2012 to 2014) and the third (2012 to 2015) round of 346 IRS, respectively (Figure 1B, Table supplement 1). These declines in parasite prevalence were observed 347 across all ages, with the greatest impacts being observed on the younger children (1-5 years) who were 348 \sim 3 times less likely to have an infection in 2015 (post-IRS) compared to 2012 (pre-IRS) (Figure 1C, Table 349 supplement 1). These reductions were however short-lived and in 2017, 32-months after the 350 discontinuation of IRS, but during SMC, overall *P. falciparum* prevalence rebounded to 41.2%, or near pre-351 IRS levels (Figure 1B, Table supplement 1). Importantly, this increase in the prevalence of infection in 2017 352 was only observed among the older age groups (i.e., \geq 6 years) (Figure 1C, Table supplement 1). This 353 difference by age group in 2017 can be attributed to SMC, which only targets children between 3-59 354 months (i.e., < 5 years). A notable increase in parasite prevalence for adolescents (11-20 years) and adults 355 (> 20 years) was found in 2017 relative to the 2012 (pre-IRS) (Figure 1C, Table supplement 1).

356

Next, we wanted to explore changes in population size measured by MOI_{var} . As this metric is based on non-overlap of *var* repertoire diversity of individual isolates, specifically non-upsA DBL α types, we investigated whether DBL α isolate repertoire similarity (or overlap), as measured by PTS, increased following the sequential interventions (i.e., IRS and SMC). Figure 2 shows that median PTS values for both upsA and non-upsA DBL α types remained low in all surveys, although the PTS distributions for both groups changed significantly at each of the study time points relative to the 2012 baseline survey (pre-IRS) (*p*-

values < 0.001, Kruskal-Wallis test) (Figure 2). Somewhat unexpectedly, the change was in the direction 363 364 of reduced similarity (i.e., less overlap) with lower median PTS scores and a larger number of isolates 365 sharing no DBLα types (i.e., PTS = 0) in 2014, 2015, and 2017 compared to 2012. Relevant to measurement 366 of MOI_{var}, the median PTS scores for non-upsA DBL α types were lower following the IRS intervention 367 (PTS_{non-upsA}: 2014 = 0.013 and 2015 = 0.013 vs. PTS_{non-upsA}: 2012 = 0.020). In 2017, the non-upsA PTS 368 distributions shifted back towards higher median PTS scores (PTS_{non-upsA} = 0.016) and fewer isolates shared 369 no DBLα types relative to 2014 and 2015 (Figure 2). To verify this pattern was not influenced by multiclonal 370 infections (MOI_{var} > 1) we also examined isolates with monoclonal infections (MOI_{var} = 1) and found that 371 this non-overlapping structure persisted regardless of infection complexity, particularly for the non-upsA 372 DBL α types (Figure supplement 4). These PTS data make clear that we were dealing with a large, highly 373 diverse parasite population where 99.9% of the isolate comparisons in all surveys had $PTS_{non-upsA}$ scores \leq 374 0.1 (i.e., shared \leq 10% of their non-upsA DBL α types), indicating that DBL α isolate repertoires were highly 375 unrelated (Figure 2). In fact, throughout the IRS, SMC, and subsequent rebound, very few DBL α isolate 376 repertoires were observed to be related, with < 0.003% isolate comparisons in each survey having a PTS_{non-} 377 $_{upsA} \ge 0.5$ (i.e., siblings or recent recombinants) (Figure 2).

378

The raw data of non-upsA DBL α isolate repertoire sizes (Figure supplement 5) were used to estimate MOI_{var} as adjusted using the Bayesian approach based on pooling the maximum *a posteriori* MOI estimates (Figure 3) and the mixture distribution (Figure supplement 6). We observed that at baseline in 2012, the majority (89.2%) of the population across all ages carried multiclonal infections (median MOI_{var} = 4 [IQR: 2 - 6]) (Figure 3A). Following the IRS intervention, the estimated MOI_{var} distributions became more positively skewed, indicating that a lower proportion of participants harboured multiclonal infections with

385 a lower median MOl_{var} in 2014 (64.5%; median MOl_{var} = 2 [IQR: 1 - 3]) and 2015 (71.4%; median MOl_{var} = 386 2 [IQR: 1 - 3]) compared to 2012 (Figure 3A). These reductions in median MOI_{var} and the proportion of 387 multiclonal infections, which were observed across all age groups (Figure 3B), are consistent with the >388 90% decrease in transmission intensity following the IRS in turn reducing exposure to new parasite 389 genomes. However, in 2017, both median MOl_{var} (3 [IQR: 2 – 4]) and the proportion of multiclonal 390 infections (78.9%) rebounded in all age groups, even among the younger children (1-5 years) 391 predominantly targeted by SMC (Figure 3). While the prevalence of infection in 2017 remained low for 392 the younger children (1-5 years), those infected still carried multiclonal infections (84.1% of those 393 infected) (Figure 3B). Although the MOl_{var} distributions across all age groups started to rebound in 2017 394 (i.e., less positively skewed compared to 2014 and 2015) they had not fully recovered to the 2012 baseline 395 patterns (Figure 3). This was most apparent among the younger children (1-5 years), as a larger proportion 396 of isolates in 2017, compared to 2012, had MOI_{var} values equal to one or two, while a smaller proportion 397 had MOI_{var} values ≥ 5 (Figure 3B).

398

399 Census population size, measured as the number of P. falciparum var repertoires circulating in the 400 population during each survey, was estimated by summation of isolate MOIvar (Figure 4, Table supplement 401 7). In 2014 during IRS, this number decreased by 72.5% relative to the 2012 baseline survey (pre-IRS) 402 (Figure 4CE), whereas prevalence decreased by 54.5% (Figure 4CE). Although census population size 403 increased slightly in 2015 relative to 2014 (Figure 4A), there were still 64.6% fewer var repertoires in the 404 population compared to 2012 (Figure 4CE) in comparison to a 42.6% decrease in prevalence (Figure 4CE). 405 Importantly this loss of var repertoires in 2014 and 2015 following the IRS intervention was seen for all 406 age groups (Figure 4B), with the greatest overall reductions (> 85%) being observed for the younger

407 children (1-5 years) (Figure 4DF). However, in 2017, the number of diverse var repertoires in the 408 population rebounded, more than doubling between 2015 and 2017 (Figure 4CE). This increase in the 409 number of var repertoires was seen for all age groups in 2017, except for the younger children (1-5 years) 410 where those up to 59 months were targeted by SMC (Figure 4BD). In fact, the greatest overall increase 411 was observed for the adolescents (11-20 years), where the number of var repertoires in 2017 was \sim 1.4 412 times higher compared to 2012 (Figure 4F). Similar trends in the number var repertoires were also 413 observed for the older children (6-10 years) and adults (>20 years) in 2017, although the rebound was not 414 as striking as that detected for the adolescents.

415

416 As census population size changed considerably during the sequential IRS and SMC interventions, we 417 investigated how the removal or loss of *P. falciparum var* repertoires and subsequent rebound in 2017 418 altered DBLa type richness, measured as the number of unique upsA and non-upsA DBLa types in the 419 parasite population in each survey. Richness at baseline in 2012 (pre-IRS) was high with a large number of 420 unique DBLa types (upsA = 2,218; non-upsA = 33,159) (Figure 5, Table supplement 2) and limited overlap 421 of var repertoires (i.e., median $PTS_{non-upsA} \leq 0.020$) seen in a relatively small study population of 685 422 microscopically positive individuals (Figure 2). In 2014, as *P. falciparum* prevalence and census population 423 size declined (Figure 4) so too did the number of DBL α types, resulting in a 32.2% and 55.3% reduction in 424 richness for the upsA and non-upsA DBLa types, respectively, compared to 2012 (Figure 5, Table 425 supplement 2). Again in 2015, as *P. falciparum* prevalence and population size remained low (Figure 4) 426 DBL α type richness was still less than that observed in 2012 (24.6% and 46.0% reduction for upsA and 427 non-upsA DBLa types, respectively) (Figure 5, Table supplement 2). Finally, in 2017, we found that upsA

428 and non-upsA DBLα type richness rebounded relative to 2014 and 2015, coincident with the increase in
429 *P. falciparum* prevalence and census population size (Figure 4, Figure 5).

430

431 Given this reduction in DBLa type richness following the IRS intervention and subsequent rebound in 2017, 432 we wanted to explore whether the loss of richness was influenced by the frequency of individual DBL α 433 types in the parasite population within and among surveys. To answer this, we defined the relative 434 frequency of individual DBL α types in all isolates in each survey (Figure 6, Figure supplement 7). We 435 discovered that individual upsA and non-upsA DBL α types were not all at equal frequencies within a survey 436 and among surveys. They could be classified as frequent (i.e., observed in 11-20 or > 20 isolates), less 437 frequent (i.e., observed in 2-10 isolates) or only seen once, at baseline in 2012 (Figure 6AB). In 2014 and 438 2015, following IRS, there was a significant increase in the proportion of upsA and non-upsA DBLa types 439 in the lower frequency categories (*p*-value < 0.001, Mann-Whitney U test), with all DBL α types becoming 440 rarer in the population (Figure 6CD). This change can be attributed to the removal of *P. falciparum var* 441 repertoires (Figure 4) with associated loss of upsA and non-upsA DBLa type richness (Figure 5), which 442 disproportionally affected those DBLa types seen once. This shift to all DBLa types becoming rarer 443 following IRS changed in 2017, where the proportion of DBLα types in the more frequent categories (i.e., 444 2-10, 11-20, or > 20 isolates) significantly increased while the proportion seen once decreased (p-values) 445 < 0.001, Mann-Whitney U tests) (Figure 6CD). Data in Figure 6 (A-D) pointed to a differential effect of the 446 IRS intervention and subsequent rebound on the less frequent upsA and non-upsA DBL α types vs. those 447 that were classified as frequent, where those DBL α types that were most frequent persisted longitudinally.

448

449 To explore this observation further we restricted the longitudinal analysis to those DBL α types from the 450 baseline survey in 2012 (pre-IRS). We compared the probability of survival for the DBL α types identified 451 at baseline in 2012 and found that the upsA DBL α types persisted significantly longer in the population 452 relative to the non-upsA DBL α types (p < 0.001, log-rank test), despite the IRS intervention. The simple 453 explanation being that although the upsA DBL α types had lower richness (Figure 5), a larger proportion 454 was classified as frequent indicating that multiple copies existed in the population compared to the non-455 upsA DBLa types (Figure 6CD). Furthermore, when we examined survival using the frequency categories, 456 the upsA and non-upsA DBL α types that were observed at multiple study time points (i.e., 2012, 2014, 457 2015, and 2017), albeit in different isolate repertoires, were those that were most frequent (i.e., observed 458 in 11-20 and >20 isolates) in the population at baseline in 2012 (Figure 6EF). As expected, the DBL α types 459 that were only observed once in 2012, were significantly less likely to be seen longitudinally (*p*-value < 460 0.001, log-rank test) (Figure 6EF). These differential changes in DBL α type richness with respect to rare vs. 461 frequent DBL α types are a consequence of changes in census population size with interventions (Figure 462 4) where each isolate repertoire is composed of many rare DBL α types as defined by PTS (Figure 2).

464 **DISCUSSION**

465 P. falciparum populations in high-transmission endemic areas in SSA, are characterised by extensive 466 diversity, high rates of recombination, as well as frequent multiclonal infections. Here we defined census 467 population size of *P. falciparum* to understand total parasite diversity in a human population and explore 468 the age-specific efficacy of malaria interventions to reduce this metric in such areas as typified by Bongo, 469 Ghana. Census population size proved more informative than parasite prevalence alone because it 470 captures "within" host parasite population size as MOI, rather than using the infected host per se as a unit 471 of population size. Whilst the concept of census population size is agnostic of how you measure MOI, the 472 extensive DBL α isolate repertoire diversity presented makes a strong case for fingerprinting parasite 473 isolates by varcoding in high transmission. This is opposed to looking at allelic diversity of a single copy 474 antigen gene, such as *csp*.

475

476 Census population size is a total enumeration or count of infections in a given population sample and over 477 a given time period in an ecological sense, distinct from the formal effective population size (N_e) used in 478 population genetics (Charlesworth, 2009). Given the low overlap between var repertoires of parasites 479 observed in monoclonal infections (MOI = 1), the census population size calculated in Bongo, Ghana 480 translates to a diversity of strains or repertoires. The distinction of census population size in terms of 481 infection counts and effective population size from population genetics has been made before for 482 pathogens, including the seasonal influenza virus and the measles virus (Bedford et al., 2011); it is also a 483 distinction made in the ecological literature for non-pathogen populations (Palstra and Fraser, 2012). The 484 census population size of a given population sample depends of course on sample size and was used here 485 for comparisons across time of samples of the same depth (i.e., ~2,000 individuals). There is, however, a

simple map between census population size and mean MOI, as one can simply divide or multiply by the sample size, respectively, to convert between the two quantities (Table supplement 7). Therefore, one can extrapolate from the census population size of a given population sample to that of the whole population of local hosts to compare across studies that differ in sampling depth. What is needed for this extrapolation is a stable mean MOI relative to the sample size or sampling depth, which is indeed the case in this study (Figure supplement 8) and can be easily checked in other studies. Given the typical duration of infection, we expect our population size to be representative of a per-generation measure.

493

494 By varcoding we identified a very large census parasite population size in a relatively small human 495 population of ~2,000 individuals at baseline and captured age-specific changes in this metric in response 496 to sequential malaria control interventions. IRS reduced the MOIvar parasite population size substantially 497 with the greatest reductions (85%) seen in the younger children (1-5 years). More than two years after 498 cessation of IRS, rebound in 2017 was rapid in all age groups, except for the younger children (1-5 years) 499 where those up to 59 months were targeted by SMC. Population sizes in adolescents (11-20 years) and 500 adults (> 20 years) showed they carried more infections in 2017 than at baseline in 2012. This is indicative 501 of a loss of immunity during IRS which may relate to the observed loss of var richness, especially the many 502 rare types. This warrants further investigation of changes in variant-specific immunity. During and 503 following the IRS and SMC interventions, var diversity remained high and var repertoire overlap remained 504 low, reflecting characteristic properties of high transmission and demonstrating the overall resilience of 505 the species to survive significant short-term perturbations. Combining interventions and targeting older 506 age groups or the whole community with chemoprevention would no doubt have a much greater impact 507 on reducing the diversity of the reservoir of infection.

508

509 What was striking about the Bongo study was the speed with which rebound in MOIvar per person and 510 census population size occurred, once the short-term IRS was discontinued. We looked for a potential 511 explanation in our genetic data. PTS and population frequency data showed that many of the DBLα types 512 occurred in multiple repertoires or genomes. This enabled the survival of these more frequent DBLa types 513 through the interventions, facilitating rebound by maintenance of this diversity. The other notable 514 population genetic result of our study was the failure to increase similarity (or relatedness by state) of var 515 repertoires by reducing transmission by > 90% via IRS. From a baseline of a very large population size with 516 very low overlap in repertoires you need outcrossing to create relatedness. However, this was less likely 517 to happen due to reduced transmission as a result of IRS. Rebound, with associated increases in 518 transmission, led to a small increase in var repertoire similarity. This is the opposite to what has been 519 observed in areas of lower transmission under intense malaria control where the intensity of interventions 520 led to increased genome similarity, as assessed by IBD, from a starting point of much lower genome 521 diversity and greater relatedness (Daniels et al., 2015).

522

523 Our molecular approach to measure population size has been to sum MOI_{var} in individual hosts with 524 microscopically-detectable infections. Like any diagnostic method there are limits to sensitivity and 525 specificity, which can be more or less tolerated dependent upon the purpose of the study. Here we have 526 looked at relative changes in population size with sequential interventions using an interrupted time series 527 study design and observed changes by measuring MOI_{var} . We have accounted for missing DBL α type data 528 where complete *var* repertoires may not have been sequenced using a Bayesian method based on 529 empirical knowledge of the measurement error. This approach has conceptual relation to the Bayesian

approach by Johnson and Larremore (Johnson and Larremore, 2022) to estimate complete repertoire size of, and overlap between, monoclonal infections from incomplete sampling of DBLα types. Our measurement of population size based on MOl_{var} will be subject to other sampling errors which may in the end be more significant (discussed in detail in Labbé et al. (Labbé et al., 2023)). For example, low parasitemia typical of asymptomatic infections, small blood volumes, clinical status, and/or within host dynamics, including synchronicity, will all create sampling problems, but these are common to all measures of MOI.

537

538 Previously, we have drawn attention to the potential underestimation of the number of DBL α types of 539 related parasites generated by a cross, when using var genotyping (Labbé et al., 2023). Such related 540 parasites must be created frequently in high transmission due to extensive outcrossing (Babiker et al., 541 1994; Paul et al., 1995). Single clone genomics experiments using biallelic SNPs from whole genome 542 sequencing data have also detected related parasites using IBD in clinical infections from humans in a 543 high-transmission area of Malawi (Nkhoma et al., 2020). Here we have analysed low- to moderate-density, 544 chronic, asymptomatic infections (see Table supplement 1) under strong immune selection in semi-545 immune hosts whom we have shown select against parasites with high PTS scores consistent with 546 relatedness by decent (Day et al., 2017; He et al., 2018; Ruybal-Pesántez et al., 2022). When considering 547 the importance of possible exclusion of parasites related by descent, the only sure way to detect such 548 parasites in high transmission is by single cell genomics, a methodology of limited application to malaria 549 surveillance due to practicality and cost of scale up. Again, the error from failure to sample infections 550 related by descent must be weighed up against the issues of under-sampling as described above.

551

552 The Bayesian approach of the varcoding method relies on the low or limiting similarity of var repertoires 553 infecting individual human hosts. As such, it would appear to break down as the var repertoire overlap 554 moves away from extremely low, and therefore, for locations with lower transmission intensity. 555 Interestingly, this is not the case in the numerical simulations of Labbé et al. (Labbé et al., 2023), for a 556 gradient of three transmission intensities, from high to low, with the original varcoding method 557 performing well across the gradient. This robustness of the method may arise from a nonlinear and fast 558 transition from low to high overlap that is accompanied by MOI changing rapidly from primarily 559 multiclonal (MOI > 1) to monoclonal (MOI = 1) infections. This matter needs to be investigated further in 560 the future, including ways to extend the Bayesian approach to explicitly include the distribution of var 561 repertoire overlap.

562

In summary, our findings provide parasite population insights into why rebound is the inevitable 563 564 consequence of such short-term IRS interventions unless you simultaneously target the highly diverse, 565 long-lived parasite population in humans, not just children < 5 years by SMC. Of potential translational 566 significance for malaria molecular surveillance, we identify new metrics, especially MOI_{var} and census 567 population size as well as var frequency category, informative to monitor and evaluate interventions in 568 high-transmission areas with multiclonal infections and high rates of outcrossing. Such metrics could be 569 used longitudinally to detect incremental gains of transmission-reducing interventions, including IRS, 570 LLINs, and vaccines to perturb the high-transmission characteristics of the parasite population in humans 571 in high-burden countries in SSA.

572

573	ACKNOWLEDGMENTS. This research was supported by Fogarty International Center at the National
574	Institutes of Health through the joint NIH-NSF-NIFA Ecology and Evolution of Infectious Diseases award
575	R01-TW009670 to K.A.K, M.P, and K.P.D; and the National Institute of Allergy and Infectious Diseases,
576	National Institutes of Health through the joint NIH-NSF-NIFA Ecology and Evolution of Infectious Diseases
577	award R01-AI149779 to A.R.O, K.A.K, M.P, and K.P.D. We wish to thank the participants, communities, and
578	the Ghana Health Service in Bongo District, Ghana for their willingness to participate in this study. We
579	would like to thank the field teams in Bongo for their technical assistance in the field, as well as the
580	laboratory personnel at the Navrongo Health Research Centre for their expertise and for undertaking the
581	sample collections and parasitological assessments.

583 **REFERENCES**

- Anderson TJC, Haubold B, Williams JT, Estrada-Franco JG, Richardson L, Mollinedo R, Bockarie M, Mokili J,
 Mharakurwa S, French N, Whitworth J, Velez ID, Brockman AH, Nosten F, Ferreira MU, Day KP,
 Estrada-Franco JG, Richardson L, Mollinedo R, Bockarie M, Mokili J, Mharakurwa S, French N,
 Whitworth J, Velez ID, Brockman AH, Nosten F, Ferreira MU, Day KP. 2000. Microsatellite markers
 reveal a spectrum of population structures in the malaria parasite Plasmodium falciparum. *Mol Biol Evol* 17:1467–1482. doi:10.1093/oxfordjournals.molbev.a026247
- Babiker HA, Ranford-Cartwright LC, Currie D, Charlwood JD, Billingsley P, Teuscher T, Walliker D. 1994.
 Random mating in a natural population of the malaria parasite Plasmodium falciparum. *Parasitology* 109:413–421. doi:10.1017/S0031182000080665
- Barry AE, Leliwa-Sytek A, Tavul L, Imrie H, Migot-Nabias F, Brown SM, McVean GA V, Day KP. 2007.
 Population genomics of the immune evasion (var) genes of Plasmodium falciparum. *PLoS Pathog* 3:e34. doi:10.1371/journal.ppat.0030034
- Bedford T, Cobey S, Pascual M. 2011. Strength and tempo of selection revealed in viral gene genealogies.
 BMC Evol Biol 11. doi:10.1186/1471-2148-11-220
- Bruce MC, Galinski MR, Barnwell JW, Donnelly CA, Walmsley M, Alpers MP, Walliker D, Day KP. 2000.
 Genetic diversity and dynamics of plasmodium falciparum and P. vivax populations in multiply
 infected children with asymptomatic malaria infections in Papua New Guinea. *Parasitology* 121 (Pt
 3:257–272. doi:10.1017/S0031182099006356
- 602 Charlesworth B. 2009. Fundamental concepts in genetics: Effective population size and patterns of
 603 molecular evolution and variation. *Nat Rev Genet*. doi:10.1038/nrg2526
- 604 Chen DS, Barry AE, Leliwa-Sytek A, Smith T-AA, Peterson I, Brown SM, Migot-Nabias F, Deloron P, Kortok
 605 MM, Marsh K, Daily JP, Ndiaye D, Sarr O, Mboup S, Day KP. 2011. A molecular epidemiological study
 606 of var gene diversity to characterize the reservoir of Plasmodium falciparum in humans in Africa. *PLoS* 607 One 6:e16629. doi:10.1371/journal.pone.0016629
- Daniels RF, Schaffner SF, Wenger E a., Proctor JL, Chang H-H, Wong W, Baro N, Ndiaye D, Fall FB, Ndiop
 M, Ba M, Milner D a., Taylor TE, Neafsey DE, Volkman SK, Eckhoff P a., Hartl DL, Wirth DF. 2015.
 Modeling malaria genomics reveals transmission decline and rebound in Senegal. *PNAS* 112:7067–
 7072. doi:10.1073/pnas.1505691112
- 612 Day KP, Artzy-Randrup Y, Tiedje KE, Rougeron V, Chen DS, Rask TS, Rorick MM, Migot-Nabias F, Deloron 613 P, Luty AJF, Pascual M. 2017. Evidence of Strain Structure in Plasmodium falciparum Var Gene 614 Repertoires Children from Gabon, Africa. **114**:E4103–E4111. in West PNAS 615 doi:10.1073/pnas.1613018114
- 616 Dietz K. 1988. Mathematical models for transmission and control of malariaMalaria: Principles and
 617 Practice of Malariology.
- Falk N, Kaestli M, Qi W, Ott M, Baea K, Cortés A, Beck H-P. 2009. Analysis of Plasmodium falciparum var
 genes expressed in children from Papua New Guinea. *Journal of infectious diseases* 200:347–356.
 doi:10.1086/600071
- Falk N, Maire N, Sama W, Owusu-Agyei S, Smith T, Beck HP, Felger I. 2006. Comparison of PCR-RFLP and
 genescan-based genotyping for analyzing infection dynamics of Plasmodium falciparum. *American*
- 623 Journal of Tropical Medicine and Hygiene **74**:944–950.

- Farnert A, Snounou G, Rooth I, Bjorkman A. 1997. Daily dynamics of Plasmodium falciparum
 subpopulations in asymptomatic children in a holoendemic area. *American Journal of Tropical Medicine and Hygiene* 56:538–547. doi:10.4269/ajtmh.1997.56.538
- Futse JE, Brayton KA, Dark MJ, Knowles DP, Palmer GH. 2008. Superinfection as a driver of genomic
 diversification in antigenically variant pathogens. *Proc Natl Acad Sci U S A* 105:2123–2127.
 doi:10.1073/pnas.0710333105
- Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S,
 Paulsen IT, James K, Eisen J a, Rutherford K, Salzberg SL, Craig A, Kyes S, Chan M-S, Nene V, Shallom
 SJ, Suh B, Peterson J, Angiuoli S, Pertea M, Allen J, Selengut J, Haft D, Mather MW, Vaidya AB, Martin
- DMA, Fairlamb AH, Fraunholz MJ, Roos DS, Ralph S a, McFadden GI, Cummings LM, Subramanian
 GM, Mungall C, Venter JC, Carucci DJ, Hoffman SL, Newbold C, Davis RW, Fraser CM, Barrell B. 2002.
 Genome sequence of the human malaria parasite Plasmodium falciparum. *Nature* 419:498–511.
 doi:10.1038/nature01097
- Ghansah A, Tiedje KE, Argyropoulos DC, Onwona CO, Deed SL, Labbé F, Oduro AR, Koram KA, Pascual M,
 Day KP. 2023. Comparison of molecular surveillance methods to assess changes in the population
 genetics of Plasmodium falciparum in high transmission. *Frontiers in Parasitology* 2:1067966.
- Gogue C, Wagman J, Tynuv K, Saibu A, Yihdego Y, Malm K, Mohamed W, Akplu W, Tagoe T, Ofosu A,
 Williams I, Asiedu S, Richardson J, Fornadel C, Slutsker L, Robertson M. 2020. An observational
 analysis of the impact of indoor residual spraying in Northern, Upper East, and Upper West Regions
 of Ghana: 2014 through 2017. *Malar J* 19:1–13. doi:10.1186/s12936-020-03318-1
- He Q, Pilosof S, Tiedje KE, Ruybal-Pesántez S, Artzy-Randrup Y, Baskerville EB, Day KP, Pascual M. 2018.
 Networks of genetic similarity reveal non-neutral processes shape strain structure in Plasmodium
 falciparum. *Nat Commun* **9**:1817. doi:10.1038/s41467-018-04219-3
- Henry JM. 2020. A hybrid model for the effects of treatment and demography on malaria superinfection. *J Theor Biol* **491**:110194.
- Jensen ATR, Magistrado P, Sharp S, Joergensen L, Lavstsen T, Chiucchiuini A, Salanti A, Vestergaard LS,
 Lusingu JP, Hermsen R, Sauerwein R, Christensen J, Nielsen MA, Hviid L, Sutherland C, Staalsoe T,
 Theander TG. 2004. Plasmodium falciparum associated with severe childhood malaria preferentially
 expresses PfEMP1 encoded by group A var genes. J Exp Med 199:1179–1190.
- 653 doi:10.1084/jem.20040274
- Johnson EK, Larremore DB. 2022. Bayesian estimation of community size and overlap from random
 subsamples. *PLoS Comput Biol* 18:1–16. doi:10.1371/journal.pcbi.1010451
- Kaestli M, Cockburn I a, Cortés A, Baea K, Rowe JA, Beck H-P. 2006. Virulence of malaria is associated with
 differential expression of Plasmodium falciparum var gene subgroups in a case-control study. *J Infect Dis* 193:1567–1574. doi:JID35650 [pii]\n10.1086/503776
- Kalmbach Y, Rottmann M, Kombila M, Kremsner PG, Beck H-P, Kun JFJ. 2010. Differential var gene expression in children with malaria and antidromic effects on host gene expression. *Journal of Infectious Diseases* 202:313–317. doi:10.1086/653586
- 662 Kassambara A, Kosinski M, Biecek P, Scheipl F. 2021. survminer: Drawing Survival Curves using ggplot2.
- Kraemer SM, Kyes SA, Aggarwal G, Springer AL, Nelson SO, Christodoulou Z, Smith LM, Wang W, Levin E,
- 664 Newbold CI, Myler PJ, Smith JD. 2007. Patterns of gene recombination shape var gene repertoires in 665 Plasmodium falciparum: comparisons of geographically diverse isolates. *BMC Genomics* **8**:45.
- 666 doi:10.1186/1471-2164-8-45

- Kraemer SM, Smith JD. 2006. A family affair: var genes, PfEMP1 binding, and malaria disease. *Curr Opin Microbiol*. doi:10.1016/j.mib.2006.06.006
- Kyriacou HM, Stone GN, Challis RJ, Raza A, Lyke KE, Thera MA, Koné AK, Doumbo OK, Plowe C V., Rowe JA.
 2006. Differential var gene transcription in Plasmodium falciparum isolates from patients with
 cerebral malaria compared to hyperparasitaemia. *Mol Biochem Parasitol* 150:211–218.
 doi:10.1016/j.molbiopara.2006.08.005
- Labbé F, He Q, Zhan Q, Tiedje KE, Argyropoulos DC, Tan MH, Ghansah A, Day KP, Pascual M. 2023. Neutral
 vs. non-neutral genetic footprints of Plasmodium falciparum multiclonal infections. *PLoS Comput Biol* 19:e1010816. doi:doi.org/10.1101/2022.06.27.497801
- LaVerriere E, Schwabl P, Carrasquilla M, Taylor AR, Johnson ZM, Shieh M, Panchal R, Straub TJ, Kuzma R,
 Watson S, Buckee CO, Andrade CM, Portugal S, Crompton PD, Traore B, Rayner JC, Corredor V, James
 K, Cox H, Early AM, MacInnis BL, Neafsey DE. 2022. Design and implementation of multiplexed
 amplicon sequencing panels to serve genomic epidemiology of infectious disease: A malaria case
 study. *Mol Ecol Resour* 2285–2303. doi:10.1111/1755-0998.13622
- Lavstsen T, Salanti A, Jensen ATR, Arnot DE, Theander TG. 2003. Sub-grouping of Plasmodium falciparum
 3D7 var genes based on sequence analysis of coding and non-coding regions. *Malar J* 2:27.
 doi:10.1186/1475-2875-2-27
- Lerch A, Koepfli C, Hofmann NE, Kattenberg JH, Rosanas-Urgell A, Betuela I, Mueller I, Felger I. 2019.
 Longitudinal tracking and quantification of individual Plasmodium falciparum clones in complex
 infections. *Sci Rep* 9:1–8. doi:10.1038/s41598-019-39656-7
- Lerch A, Koepfli C, Hofmann NE, Messerli C, Wilcox S, Kattenberg JH, Betuela I, O'Connor L, Mueller I,
 Felger I. 2017. Development of amplicon deep sequencing markers and data analysis pipeline for
 genotyping multi-clonal malaria infections. *BMC Genomics* 18:1–13. doi:10.1186/s12864-017-4260y
- Markwalter CF, Menya D, Wesolowski A, Esimit D, Lokoel G, Kipkoech J, Freedman E, Sumner KM, Abel L,
 Ambani G, Meredith HR, Taylor SM, Obala AA, O'Meara WP. 2022. Plasmodium falciparum
 importation does not sustain malaria transmission in a semi-arid region of Kenya. *PLOS Global Public Health* 2:e0000807. doi:10.1371/journal.pgph.0000807
- Nelson CS, Sumner KM, Freedman E, Saelens JW, Obala AA, Mangeni JN, Taylor SM, O'Meara WP. 2019.
 High-resolution micro-epidemiology of parasite spatial and temporal dynamics in a high malaria
 transmission setting in Kenya. *Nat Commun* 10. doi:10.1038/s41467-019-13578-4
- Nkhoma SC, Trevino SG, Gorena KM, Nair S, Khoswe S, Jett C, Garcia R, Daniel B, Dia A, Terlouw DJ, Ward
 SA, Anderson TJC, Cheeseman IH. 2020. Co-transmission of Related Malaria Parasite Lineages Shapes
 Within-Host Parasite Diversity. *Cell Host Microbe* 27:93-103.e4. doi:10.1016/j.chom.2019.12.001
- Normark J, Nilsson D, Ribacke U, Winter G, Moll K, Wheelock CE, Bayarugaba J, Kironde F, Egwang TG,
 Chen Q, Andersson B, Wahlgren M. 2007. PfEMP1-DBL1alpha amino acid motifs in severe disease
 states of Plasmodium falciparum malaria. *Proc Natl Acad Sci U S A* 104:15835–40.
 doi:10.1073/pnas.0610485104
- Otto TD, Assefa SA, Böhme U, Sanders MJ, Kwiatkowski DP, Berriman M, Newbold C. 2019. Evolutionary
 analysis of the most polymorphic gene family in falciparum malaria. *Wellcome Open Res* 4:1–29.
 doi:10.12688/wellcomeopenres.15590.1
- 708Palstra FP, Fraser DJ. 2012. Effective/census population size ratio estimation: A compendium and709appraisal. Ecol Evol 2:2357–2365. doi:10.1002/ece3.329

- Paul RE, Packer MJ, Walmsley M, Lagog M, Ranford-Cartwright LC, Paru R, Day KP. 1995. Mating patterns
 in malaria parasite populations of Papua New Guinea. *Science (1979)* 269:1709–1711.
- R Core Team. 2018. R: A Language and Environment for Statistical Computing. *R Foundation for Statistical Computing*.
- Rask TS, Hansen D, Theander TG, Pedersen AG, Lavstsen T, Gorm Pedersen A, Lavstsen T, Pedersen AG,
 Lavstsen T, Gorm Pedersen A, Lavstsen T. 2010. Plasmodium falciparum erythrocyte membrane
 protein 1 diversity in seven genomes divide and conquer. *PLoS Comput Biol* 6:e1000933.
 doi:10.1371/journal.pcbi.1000933
- Rottmann M, Lavstsen T, Mugasa JP, Kaestli M, Jensen ATR, Müller D, Theander T, Beck H-PP. 2006.
 Differential expression of var gene groups is associated with morbidity caused by Plasmodium
 falciparum infection in Tanzanian children. *Infect Immun* 74:3904–3911. doi:10.1128/IAI.02073-05
- Ruybal-Pesántez S, Tiedje KE, Pilosof S, Tonkin-Hill G, He Q, Rask TS, Amenga-Etego L, Oduro AR, Koram
 KA, Pascual M, Day KP. 2022. Age-specific patterns of DBLa var diversity can explain why residents of
 high malaria transmission areas remain susceptible to Plasmodium falciparum blood stage infection
 throughout life. *Int J Parasitol* 20:721–731.
- Ruybal-Pesántez S, Tiedje KE, Tonkin-Hill G, Rask TS, Kamya MR, Greenhouse B, Dorsey G, Duffy MF, Day
 KP. 2017. Population genomics of virulence genes of Plasmodium falciparum in clinical isolates from
 Uganda. *Sci Rep* 7:11810. doi:10.1038/s41598-017-11814-9
- Sjoberg, D, Whiting K, Curry M, Lavery J, Larmarange J. 2021. Reproducible Summary Tables with the
 gtsummary Package. *R J* 13:570–580.
- Smith T, Felger I, Fraser-Hurt N, Beck H-PP. 1999. Effect of insecticide-treated falciparum infections bed
 nets on the dynamics of multiple Plasmodium falciparum infections. *Trans R Soc Trop Med Hyg* 93
 (Supp):S1/53-S1/57. doi:10.1016/S0035-9203(99)90328-0
- Speed D, Balding DJ. 2015. Relatedness in the post-genomic era: Is it still useful? *Nat Rev Genet* 16:33–44.
 doi:10.1038/nrg3821
- 735 Stevenson M. 2020. epiR: Tools for the analysis of epidemiological data.
- Sumner KM, Freedman E, Abel L, Obala A, Pence BW, Wesolowski A, Meshnick SR, Prudhomme-O'Meara
 W, Taylor SM. 2021. Genotyping cognate Plasmodium falciparum in humans and mosquitoes to
 estimate onward transmission of asymptomatic infections. *Nat Commun* 12:1–12.
 doi:10.1038/s41467-021-21269-2
- Tan MH, Shim H, Chan Y, Day KP. 2023. Unravelling chaos for malaria surveillance : Relationship between
 DBLα types and var genes in Plasmodium falciparum. *Frontiers in Parasitology* 1.
 doi:https://doi.org/10.3389/fpara.2022.1006341
- Tessema SK, Hathaway NJ, Teyssier NB, Murphy M, Chen A, Aydemir O, Duarte EM, Simone W, Colborn J,
 Saute F, Crawford E, Aide P, Bailey JA, Greenhouse B. 2020. Sensitive, highly multiplexed sequencing
 of microhaplotypes from the Plasmodium falciparum heterozygome. *Journal of Infectious Diseases* 225:1227–1237.
- 747 Therneau T. 2023. A Package for Survival Analysis in R.
- Tiedje KE, Oduro AR, Agongo G, Anyorigiya T, Azongo D, Awine T, Ghansah A, Pascual M, Koram KA, Day
 KP. 2017. Seasonal Variation in the Epidemiology of Asymptomatic Plasmodium falciparum Infections
 Across Two Catchment Areas in Bongo District, Ghana. Am J Trop Med Hyg 97:199–212.
 doi:10.4269/ajtmh.16-0959
- Tiedje KE, Oduro AR, Bangre O, Amenga-Etego L, Dadzie SK, Appawu MA, Frempong K, Asoala V, Charles
 A Narh, Samantha L Deed, Ruybal-Pesántez S, Argyropoulos DC, Anita Ghansah, Agyei SA, Segbaya S,

754 Desewu K, Williams I, Simpson JA, Malm K, Pascual M, Koram KA, Day KP. 2022. Indoor residual 755 spraying with a non-pyrethroid insecticide reduces the reservoir of Plasmodium falciparum in a high-756 transmission area in northern Ghana. PLOS Global Public Health 2:e0000285. 757 doi:10.1371/iournal.pgph.0000285

- US Agency for International Development (USAID) Global Health Supply Chain Program. 2020. Technical
 Breif: Data visability makes all the difference in Ghana's 2018 LLIN mass distribution campaign.
- US President's Malaria Initiative Africa IRS (AIRS) Project. 2016. Entomological monitoring of the PMI AIRS
 program in northern Ghana: 2016 annual report. Bethesda, Marland, USA.
- Wagman J, Gogue C, Tynuv K, Mihigo J, Bankineza E, Bah M, Diallo D, Saibu A, Richardson JH, Kone D,
 Fomba S, Bernson J, Steketee R, Slutsker L, Robertson M. 2018. An observational analysis of the
 impact of indoor residual spraying with non-pyrethroid insecticides on the incidence of malaria in
 Ségou Region, Mali: 2012–2015. *Malar J* 17:19. doi:10.1186/s12936-017-2168-2
- Warimwe GM, Fegan G, Musyoki JN, Newton CRJC, Opiyo M, Githinji G, Andisi C, Menza F, Kitsao B, Marsh
 K, Bull PC. 2012. Prognostic indicators of life-threatening malaria are associated with distinct parasite
 variant antigen profiles. *Sci Transl Med* 4:129ra45. doi:10.1126/scitranslmed.3003247
- Warimwe GM, Keane TM, Fegan G, Musyoki JN, Newton CRJC, Pain A, Berriman M, Marsh K, Bull PC. 2009.
 Plasmodium falciparum var gene expression is modified by host immunity. *Proc Natl Acad Sci U S A* 106:21801–21806.
- Watson OJ, Okell LC, Hellewell J, Slater HC, Unwin HJT, Omedo I, Bejon P, Snow RW, Noor AM, Rockett K,
 Hubbart C, Nankabirwa JI, Greenhouse B, Chang HH, Ghani AC, Verity R. 2021. Evaluating the
 Performance of Malaria Genetics for Inferring Changes in Transmission Intensity Using Transmission
 Modeling. *Mol Biol Evol* 38:274–289. doi:10.1093/molbev/msaa225
- WHO. 2012. WHO Policy Recommendation: Seasonal Malaria Chemoprevention (SMC) for Plasmodium
 falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa.
- 778 WHO/GMP. 2017. A Framework for Malaria Elimination, Geneva World Health Organization.
- Wickham H, Averick M, Bryan J, Chang W, McGowan L, François R, Grolemund G, Hayes A, Henry L, Hester
 J, Kuhn M, Pedersen T, Miller E, Bache S, Müller K, Ooms J, Robinson D, Seidel D, Spinu V, Takahashi
- 781 K, Vaughan D, Wilke C, Woo K, Yutani H. 2019. Welcome to the Tidyverse. J Open Source Softw
 782 4:1686. doi:10.21105/joss.01686
- World Health Organization. 2022. World Malaria Report 2022, World Health Organization. doi:ISBN 978
 92 4 1564403
- Zhang X, Deitsch KW. 2022. The mystery of persistent, asymptomatic Plasmodium falciparum infections.
 Curr Opin Microbiol **70**:102231. doi:10.1016/j.mib.2022.102231
- 787
- 788

789 DATA AVAILABILITY STATEMENT. The sequences utilized in this study are publicly available in GenBank 790 under BioProject Number: PRJNA 396962. All data associated with this study are available in the main text, 791 the Supporting Information, or upon reasonable request for research purposes to the corresponding 792 author, Prof. Karen Day (karen.day@unimelb.edu.au). All custom code is available in an open source 793 repository: (1) DBL α Cleaner pipeline is available athttps://github.com/UniMelb-Day-Lab/DBL α Cleaner, (2) 794 clusterDBLalpha pipeline is available at https://github.com/Unimelb-Day-Lab/clusterDBLalpha, and the (3) 795 classifyDBLalpha pipeline is available at https://github.com/Unimelb-Day-Lab/classifyDBLalpha. A dataset 796 to demo this custom code is available at https://github.com/UniMelb-Day-Lab/tutorialDBLalpha. For 797 additional information on the use of the Bayesian approach to estimate MOlyar please see 798 https://github.com/gzhan321/Bayesian-formulation-varcoding-MOI-estimation.

799

800 BENEFIT-SHARING STATEMENT. A research collaboration was developed with scientists from Ghana 801 based at the Navrongo Health Research Centre and the Noguchi Memorial Institute for Medical Research. 802 All collaborators are included as co-authors and the relevant results from the research has been shared 803 with key stakeholders and the local community (i.e., Paramount Chief of Bongo, divisional Chiefs, Queen 804 Mothers, and community members), the Bongo District and Upper East Regional Health Directorates, as 805 well as Ghana National Malaria Elimination Programme. Before this research was undertaken, informed 806 consent was sought and obtained from the key stakeholders, traditional leadership, and the local 807 community in Bongo District. In addition, members of the local community were trained as field workers 808 and were directly involved in liaising with the community and in the collection of the study data. The 809 contribution of these individuals to this research is described in the Acknowledgements. This research 810 addresses a priority concern regarding malaria control and the impact of interventions. These concerns

- 811 are relevant for both the local community in Bongo District, as well as for the National Malaria Elimination812 Programme in Ghana.
- 813

814	AUTHOR CONTRIBUTIONS. K.P.D and M.P conceptualized the study of population size using MOIvar. K.A.K
815	and K.P.D conceived and designed the field study with input from A.R.O and K.E.T, who together with O.B
816	coordinated the field studies. K.E.T, S.R-P, and S.L.D processed the samples and performed the genotyping
817	experiments. G.T-H developed and validated the bioinformatic pipelines. K.E.T, S.R-P, and D.C.A
818	processed, cleaned, and curated the datasets for analysis. Q.Z developed and implemented the Bayesian
819	estimations. K.E.T, Q.Z, M.P, and K.P.D analysed the data with contributions from S.R-P, Q.H, and M-H.T.
820	K.E.T and Q.Z visualized the data. K.P.D, M.P, and K.E.T wrote the original draft of the manuscript. Q.Z.,
821	S.R-P, G.T-H, Q.H, M-H.T, D.C.A, S.L.D, O. B, A.R.O, and K.AK reviewed and edited manuscript. M.P and K.P.D
822	supervised the research. A.R.O, K.A.K, M.P, and K.P.D acquired the funding.

- 823
- 824 **COMPETING INTERESTS.** The authors declare no competing interests.

FIGURES 825



826

827 Figure 1. Study design and changes in the prevalence of microscopic *P. falciparum* infection following 828 the IRS and SMC interventions in Bongo, Ghana. (A) Four age-stratified cross-sectional surveys of ~2,000 829 participants per survey were conducted in Bongo, Ghana at the end of the wet seasons in October 2012 830 (Survey 1, baseline pre-IRS, red), October 2014 (Survey 2, during IRS, orange), October 2015 (Survey 3, post-IRS, green), and October 2017 (Survey 4, SMC, purple) (Table supplement 1) (see Materials and 831 832 Methods). The three rounds of IRS (grey areas) were implemented between 2013 and 2015 (Tiedje et al., 833 2022). SMC was distributed to all children < 5 years of age during the wet seasons in 2016 (two rounds 834 between August – September 2016) and 2017 (four rounds between September – December 2017) 835 (Gogue et al., 2020). Both IRS and SMC were implemented against a background of widespread LLIN usage (Tiedje et al., 2022). Prevalence of microscopic P. falciparum infections (%) in the (B) study population and 836 837 (C) for all age groups (years) in each survey. Error bars represent the upper and lower limits of the 95%

838 confidence interval (CI) calculated using the Wald Interval.



839 840 Figure 2. Sharing of upsA and non-upsA DBLa types among the DBLa isolate repertoires in 2012 (pre-IRS, red), 2014 (during IRS, orange), 2015 (post-IRS, green), and 2017 (SMC, purple). The overlapping 841 842 density and violin plots (upper right-hand corners) show the distribution of PTS scores (i.e., DBL α isolate 843 repertoire similarity) between the (A) upsA and (B) non-upsA DBL α isolate repertoires for those isolates 844 with DBL α sequencing data (Table supplement 2) in each survey. The PTS scales in the density plots have 845 been zoomed-in to provide better visualization of the upsA and non-upsA DBL α types PTS distributions. 846 The colored dashed lines in the density plots indicate the median PTS scores in each survey for the upsA 847 (2012 (red) = 0.078, 2014 (orange) = 0.063, 2015 (green) = 0.054, and 2017 (purple) = 0.064) and non-848 upsA (2012 (red) = 0.020, 2014 (orange) = 0.013, 2015 (green) = 0.013, and 2017 (purple) = 0.016) DBLα 849 types. Note: The non-upsA median PTS values in 2014 (orange) and 2015 (green) were both 0.013 and 850 overlap in the figure. In the PTS violin plots the central box plots indicate the medians (centre line), 851 interquartile ranges (IQR, upper and lower quartiles), whiskers (1.5x IQR), and outliers (points).



852

Figure 3. MOI_{var} distributions in 2012 (pre-IRS, red), 2014 (during IRS, orange), 2015 (post-IRS, green), and 2017 (SMC, purple) based on pooling the maximum *a posteriori* MOI estimates. Estimated MOI_{var} distributions for the (A) study population and (B) for all age groups (years) in each survey for those isolates with DBL α sequencing data (Table supplements 2 and 7). The median MOI_{var} values are indicated with the black dashed lines and have been provided in the top right corner (median MOI_{var} value [interquartile range, upper and lower quartiles]) along with the percentage of *P. falciparum* infections that were multiclonal (MOI_{var} > 1) in each survey and age group (years).



860

861 Figure 4. Estimated number and relative change in the number of *P. falciparum var* repertoires in 862 2012 (pre-IRS, red), 2014 (during IRS, orange), 2015 (post-IRS, green), and 2017 (SMC, purple). The 863 estimated number of var repertoires (i.e., census population size) for those isolates with DBLa sequencing 864 data (Table supplements 2 and 7) in the (A) study population and (B) for all age groups (years). The 865 estimated number of var repertoires vs. P. falciparum prevalence for (C) study population and (D) for all 866 age groups (years) (Table supplement 7). The percentage change in *P. falciparum* prevalence (black dotted 867 line) and the estimated number of var repertoires (black solid line) in 2014, 2015, and 2017 compared to 868 the 2012 baseline survey (red dashed horizontal line at 0% change) for the (E) study population and (F) 869 for all age groups (years). Error bars in (A-D) represent the upper and lower limits of the 95% confidence 870 intervals (95% CIs). The 95% CIs for the number of var repertoires (i.e., census population size) were

- 871 calculated based on a bootstrap approach. We resampled 10,000 replicates from the original population-
- 872 level distribution with replacement. Each resampled replicate has the same size as the original sample.
- 873 We then derive the 95% CI based on the distribution of the resampled replicates. The 95% CIs for *P*.
- 874 *falciparum* prevalence (%) were calculated using the Wald Interval.



875

• 2012 • 2014 • 2015 • 2017

876 Figure 5. UpsA and non-upsA DBLa type richness in 2012 (pre-IRS, red), 2014 (during IRS, orange), 2015 (post-IRS, green), and 2017 (SMC, purple). Number of unique (A) upsA and (B) non-upsA DBLa 877 878 types (i.e., richness) observed in each survey vs. P. falciparum prevalence based on those isolates with 879 DBL α sequencing data (Table supplement 2). Error bars represent the upper and lower limits of the 95% 880 confidence intervals (95% CIs) for the P. falciparum prevalence (%; x-axis) and ± 2 standard deviations (± 881 2SD) for the number of unique upsA and non-upsA DBLa types (y-axis). The 95% CIs for P. falciparum prevalence (%) were calculated using the Wald Interval. The ± 2SD for the number of unique upsA and 882 883 non-upsA DBLa types were calculated based on a bootstrap approach. We resampled 10,000 replicates 884 from the original population-level distribution with replacement. Each resampled replicate has the same 885 size as the original sample. We then derive the standard deviation (SD) based on the distribution of the 886 resampled replicates.





888 Figure 6. UpsA and non-upsA DBLa type frequencies and survival in 2012 (pre-IRS, red), 2014 (during IRS, orange), 2015 (post-IRS, 889 green), and 2017 (SMC, purple). Heatmaps showing the patterns of diversity for the (A) upsA and (B) non-upsA DBLa types. The 890 columns represent all the upsA and non-upsA DBLα types observed in the four surveys, and the rows represent each of the 2,802 upsA 891 DBLa types and the 50,436 non-upsA DBLa types (Table supplement 2). White rows are used to denote the absence of a specific DBLa 892 type, while the presence of a DBL atype is indicated in colour and further categorised (colour gradations) based on the frequency or the 893 number of times (i.e., number of isolates) a DBLα type was observed in each survey (Frequency categories: 1, 2-10, 11-20, > 20 isolates; 894 Note the frequency category cut-offs were chosen based on the frequency distributions in Figure supplement 7). The proportions of (C) Impact of IRS and SMC on census population size (Updated 31_07_24) 42

895 upsA and (**D**) non-upsA DBLα types in each survey based on the number of times (i.e., number of isolates) they were observed in each 896 survey. Kaplan-Meier survival curves for the (E) upsA and (F) non-upsA DBLα types across time (2012 to 2017) categorised based on 897 their frequency at baseline in 2012 (pre-IRS, red). The colored shaded areas represent the upper and lower limits of the 95% confidence 898 intervals (95% CIs) with the number (N) of upsA and non-upsA DBLa types in each frequency category are provided in parenthesis. These 899 survival curves include only those upsA (N = 2,218) and non-upsA (N = 33,159) DBL α types that were seen at baseline in 2012 (pre-IRS) 900 as indicated in red (Table supplement 2). The x-axis indicates time where time "0" denotes 2012 (pre-IRS), "1" denotes 2014 (during 901 IRS), "2" denotes 2015 (post-IRS), and finally "3" denotes 2017 (SMC). Note: In the survival curves the 11-20 and > 20 frequency 902 categories for both the (E) upsA and (F) non-upsA DBLa types overlap in the figure.